文献速递妇产影像US

在11-13周筛查早产型子痫前期时替换或添加妊娠相关血浆蛋白A的影响

Impact of replacing or adding pregnancy-associated plasma protein-A at 11-13 weeks on screening for preterm pre-eclampsia.
PubMed 文献 · Ultrasound Obstet Gynecol · 2022-01-01

本研究为6546例单胎妊娠前瞻性筛查的二次分析,于孕11-13周联合母体病史、平均动脉压、子宫动脉搏动指数、胎盘生长因子及妊娠相关血浆蛋白A评估早产型子痫前期风险。用妊娠相关血浆蛋白A替代胎盘生长因子时AUC及10%假阳性率下检出率均低于含胎盘生长因子方案,但差异未达统计学显著;联合使用两者未额外检出病例。

要点

  • 含胎盘生长因子方案AUC 0.854、10%假阳性率检出率59.46%,优于以妊娠相关血浆蛋白A替代方案(AUC 0.813、51.35%)。
  • 以妊娠相关血浆蛋白A替代胎盘生长因子时,个体层面额外漏检3例(8.1%)早产型子痫前期。
  • 在母体病史等标志物基础上加用妊娠相关血浆蛋白A未额外检出任何早产型子痫前期病例。

核心结论

  • 在个体病例层面,采用妊娠相关血浆蛋白A替代胎盘生长因子的筛查策略会降低早产型子痫前期的检出,与既往文献一致。

研究设计与样本

  • 非干预性筛查研究的二次分析,纳入2016年12月至2018年6月前瞻性筛查的6546例单胎妊娠,所有孕妇和临床医生对早产型子痫前期风险设盲。

诊断标准与关键数值

  • 含胎盘生长因子联合母体病史、平均动脉压、子宫动脉搏动指数的AUC为0.854、10%假阳性率下检出率59.46%;以妊娠相关血浆蛋白A替代后AUC 0.813、检出率51.35%;两者同时使用AUC 0.855、检出率59.46%。

临床应用与阅片要点

  • 采用竞争风险模型、生物标志物以中位数倍数表示进行早产型子痫前期风险筛查;以妊娠相关血浆蛋白A替代胎盘生长因子在个体层面会减少检出。

局限性

  • 以妊娠相关血浆蛋白A替代胎盘生长因子的AUC差异未达统计学显著(ΔAUC 0.04,P=0.095)。
  • 同时使用妊娠相关血浆蛋白A和胎盘生长因子的AUC差异未达统计学显著(ΔAUC 0.002,P=0.423)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To assess whether pregnancy-associated plasma protein-A (PAPP-A) alters or provides equivalent screening performance as placental growth factor (PlGF) when screening for preterm pre-eclampsia (PE) at 11-13 weeks of gestation.

METHODS: This was a secondary analysis of a non-intervention screening study of 6546 singleton pregnancies that were screened prospectively for preterm PE in the first trimester between December 2016 and June 2018. Patient-specific risks for preterm PE were estimated by maternal history, mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), PlGF and PAPP-A. A competing-risks model with biomarkers expressed as multiples of the median was used. All women and clinicians were blinded to the risk for preterm PE. The performance of screening for preterm PE using PlGF vs PAPP-A vs both PAPP-A and PlGF was assessed by comparing areas under the receiver-operating-characteristics (AUC) curves. McNemar's test was used to compare detection rate at a fixed false-positive rate (FPR) of 10%.

RESULTS: PlGF and PAPP-A were measured in 6546 women, of whom 37 developed preterm PE. The AUC and detection rate at 10% FPR using PlGF in combination with maternal history, MAP and UtA-PI were 0.854 and 59.46%, respectively. The respective values were 0.813 and 51.35% when replacing PlGF with PAPP-A and 0.855 and 59.46% when using both PAPP-A and PlGF. Statistically non-significant differences were noted in AUC when replacing PlGF with PAPP-A (ΔAUC, 0.04; P = 0.095) and when using both PAPP-A and PlGF (ΔAUC, 0.002; P = 0.423). However, on an individual case basis, screening using PlGF in conjunction with maternal history, MAP and UtA-PI identified three (8.1%) additional pregnancies that developed preterm PE and that were not identified when replacing PlGF with PAPP-A. Screening using PAPP-A in addition to maternal history and other biomarkers did not identify any additional pregnancies.

CONCLUSION: On an individual case basis, adoption of a screening strategy that uses PAPP-A instead of PlGF results in reduced detection of preterm PE, consistent with previous literature. © 2022 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Wah YMI, Sahota DS, Chaemsaithong P, et al. Impact of replacing or adding pregnancy-associated plasma protein-A at 11-13 weeks on screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol. 2022. PMID: 35468236. doi:10.1002/uog.24918

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。